The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Board Of Directors

 

Torsten Goesch
MD, MBA, PhD,

Chairman of the Board
since 2015
Achim Kaufhold
MD,
Board Member
since 2021
Marianne Kock
MSc, MBA,
Board member
since 2021
Professional experience Professional experience Professional experience
  • Dependent in relation to the company, independent in relation to its senior executives and major shareholders.

  • Dr. Torsten Goesch has been Director of Rosetta Capital’s secondary life science investments since 2002

  • Has served as the General Manager for the German Speaking Countries at Biogen from 1997-1999

  • Commercial Head of Merck KGaA’s worldwide generics drug business Merck Generics
  • Independent in relation to the company, to its senior executives and major shareholders.

  • Currently serves as CMO of Hansa Biopharma.

  • Has previously served as CEO of Affitech and Pharmexa (both companies merged)

  • CMO of companies such as Basilea Pharmaceutica, Chiron (acquired by Novartis) and Berna Biotech (now Johnson & Johnson)
  • Independent in relation to the company, to its senior executives and major shareholders.

  • Currently serves as General Manager at Ferring Pharmaceuticals’ IPC Development Unit in Copenhagen.

  • Board member of Ferring Pharmaceutical (DK), Syntese (DK), Izvarino Pharma (Rus), NanoPharm (Rus) and Asarina (SE)

  • Previously, board member of Fertin Pharma (DK), Bionor Pharma (NO), Egalet (DK), Forward Pharma (DK) and Gastrotech Pharma (DK)
Educational background Educational background Educational background
  • Doctor of Medicine (MD) and Ph.D. from Heinrich Heine University Düsseldorf

  • Master of Management (MBA) from Northwestern University’s
    J.L. Kellogg Graduate School of Management
  • Doctor of Medicine from the University of Cologne and holds a professorship in Medical Microbiology and Infectious Diseases at the University of Aachen, Germany
  • Master’s degree in Pharmacy from Danish University of Pharmacy

  • Executive Master’s degree in Business Administration from Scandinavian International Management Institute

 

 

 

 

 

 

 

 

 

 

Henrik Moltke
MSc,
Board Member
since 2021
Mattias Klintemar
MBA,
Board Member
since 2021
Professional experience Professional experience
  • Independent in relation to the company, to its senior executives and major shareholders.

  • Currently Henrik is Chairman of the board for Valeos Pharma A/S

  • Chairman of the board "Werner Richter og Hustrus Legat" a charity foundation

  • Board member of Initiator Pharma A/S (INIT).

  • Former CFO at Oncology Venture A/S (Nasdaq First North Growth Market Stockholm)

     

  • Dependent in relation to the company, independent in relation to its senior executives and major shareholders

  • Currently serves as Director of Investments at Östersjöstiftelsen

  • Has among others worked at ABG Sundal Collier and served as CEO at Morphic Technologies, CFO at Hexaformer, Chairman of the board at Dilafor and board member of Moberg Pharma, Axelar, Phoniro and DBT.

  • Board member at Oatly, Palette Life Sciences and Velove.
Educational background Educational background
  • Msc (Econ) – cand.merc., Strategy and International Economics at Copenhagen Business School
  • Bachelor of Business Administration (BBA), Accounting and Finance from Karlstad Universitett